343 related articles for article (PubMed ID: 32321509)
1. Effect of CIP2A and its mechanism of action in the malignant biological behavior of colorectal cancer.
Chen W; Liang JL; Zhou K; Zeng QL; Ye JW; Huang MJ
Cell Commun Signal; 2020 Apr; 18(1):67. PubMed ID: 32321509
[TBL] [Abstract][Full Text] [Related]
2. FL118 inhibits viability and induces apoptosis of colorectal cancer cells via inactivating the CIP2A/PP2A axis.
Lin X; Gao M; Zhang A; Tong J; Zhang X; Su Q; Yang Z; Gao H; Jiang G
Life Sci; 2019 Dec; 239():117074. PubMed ID: 31751585
[TBL] [Abstract][Full Text] [Related]
3. Overexpression of CIP2A is an independent prognostic indicator in nasopharyngeal carcinoma and its depletion suppresses cell proliferation and tumor growth.
Liu N; He QM; Chen JW; Li YQ; Xu YF; Ren XY; Sun Y; Mai HQ; Shao JY; Jia WH; Kang TB; Zeng MS; Ma J
Mol Cancer; 2014 May; 13():111. PubMed ID: 24884612
[TBL] [Abstract][Full Text] [Related]
4. MYC-dependent regulation and prognostic role of CIP2A in gastric cancer.
Khanna A; Böckelman C; Hemmes A; Junttila MR; Wiksten JP; Lundin M; Junnila S; Murphy DJ; Evan GI; Haglund C; Westermarck J; Ristimäki A
J Natl Cancer Inst; 2009 Jun; 101(11):793-805. PubMed ID: 19470954
[TBL] [Abstract][Full Text] [Related]
5. Euxanthone suppresses tumor growth and metastasis in colorectal cancer via targeting CIP2A/PP2A pathway.
Wang N; Zhou F; Guo J; Zhu H; Luo S; Cao J
Life Sci; 2018 Sep; 209():498-506. PubMed ID: 30144452
[TBL] [Abstract][Full Text] [Related]
6. CIP2A is a predictor of survival and a novel therapeutic target in bladder urothelial cell carcinoma.
Xue Y; Wu G; Wang X; Zou X; Zhang G; Xiao R; Yuan Y; Long D; Yang J; Wu Y; Xu H; Liu F; Liu M
Med Oncol; 2013 Mar; 30(1):406. PubMed ID: 23275123
[TBL] [Abstract][Full Text] [Related]
7. CIP2A influences survival in colon cancer and is critical for maintaining Myc expression.
Wiegering A; Pfann C; Uthe FW; Otto C; Rycak L; Mäder U; Gasser M; Waaga-Gasser AM; Eilers M; Germer CT
PLoS One; 2013; 8(10):e75292. PubMed ID: 24098375
[TBL] [Abstract][Full Text] [Related]
8. Cancerous inhibitor of protein phosphatase 2A is overexpressed in cervical cancer and upregulated by human papillomavirus 16 E7 oncoprotein.
Liu J; Wang X; Zhou G; Wang H; Xiang L; Cheng Y; Liu W; Wang Y; Jia J; Zhao W
Gynecol Oncol; 2011 Aug; 122(2):430-6. PubMed ID: 21575984
[TBL] [Abstract][Full Text] [Related]
9. CIP2A is associated with human breast cancer aggressivity.
Côme C; Laine A; Chanrion M; Edgren H; Mattila E; Liu X; Jonkers J; Ivaska J; Isola J; Darbon JM; Kallioniemi O; Thézenas S; Westermarck J
Clin Cancer Res; 2009 Aug; 15(16):5092-100. PubMed ID: 19671842
[TBL] [Abstract][Full Text] [Related]
10. Cip2a promotes cell cycle progression in triple-negative breast cancer cells by regulating the expression and nuclear export of p27Kip1.
Liu H; Qiu H; Song Y; Liu Y; Wang H; Lu M; Deng M; Gu Y; Yin J; Luo K; Zhang Z; Jia X; Zheng G; He Z
Oncogene; 2017 Apr; 36(14):1952-1964. PubMed ID: 27694903
[TBL] [Abstract][Full Text] [Related]
11. CIP2A regulates MYC translation (via its 5'UTR) in colorectal cancer.
Denk S; Schmidt S; Schurr Y; Schwarz G; Schote F; Diefenbacher M; Armendariz C; Dejure F; Eilers M; Wiegering A
Int J Colorectal Dis; 2021 May; 36(5):911-918. PubMed ID: 33078202
[TBL] [Abstract][Full Text] [Related]
12. CIP2A mediates prostate cancer progression via the c-Myc signaling pathway.
Guo Z; Liu D; Su Z
Tumour Biol; 2015 Jun; 36(6):4777-83. PubMed ID: 25636449
[TBL] [Abstract][Full Text] [Related]
13. CIP2A is overexpressed in non-small cell lung cancer and correlates with poor prognosis.
Dong QZ; Wang Y; Dong XJ; Li ZX; Tang ZP; Cui QZ; Wang EH
Ann Surg Oncol; 2011 Mar; 18(3):857-65. PubMed ID: 20842459
[TBL] [Abstract][Full Text] [Related]
14. CIP2A is overexpressed in gastric cancer and its depletion leads to impaired clonogenicity, senescence, or differentiation of tumor cells.
Li W; Ge Z; Liu C; Liu Z; Björkholm M; Jia J; Xu D
Clin Cancer Res; 2008 Jun; 14(12):3722-8. PubMed ID: 18559589
[TBL] [Abstract][Full Text] [Related]
15. CIP2A overexpression is associated with c-Myc expression in colorectal cancer.
Böckelman C; Koskensalo S; Hagström J; Lundin M; Ristimäki A; Haglund C
Cancer Biol Ther; 2012 Mar; 13(5):289-95. PubMed ID: 22310977
[TBL] [Abstract][Full Text] [Related]
16. Cancerous inhibitor of protein phosphatase 2A (CIP2A) is an independent prognostic marker in wild-type KRAS metastatic colorectal cancer after colorectal liver metastasectomy.
Chen KF; Yen CC; Lin JK; Chen WS; Yang SH; Jiang JK; Lan YT; Lin CC; Yu HC; Hsu HM; Lin WL; Teng HW
BMC Cancer; 2015 Apr; 15():301. PubMed ID: 25896895
[TBL] [Abstract][Full Text] [Related]
17. CIP2A is a predictor of poor prognosis in colon cancer.
Teng HW; Yang SH; Lin JK; Chen WS; Lin TC; Jiang JK; Yen CC; Li AF; Chen PC; Lan YT; Lin CC; Hsu YN; Wang HW; Chen KF
J Gastrointest Surg; 2012 May; 16(5):1037-47. PubMed ID: 22328001
[TBL] [Abstract][Full Text] [Related]
18. Clinical significance of sCIP2A levels in breast cancer.
Xing ML; Lu YF; Wang DF; Zou XY; Zhang SX; Yun Z
Eur Rev Med Pharmacol Sci; 2016; 20(1):82-91. PubMed ID: 26813457
[TBL] [Abstract][Full Text] [Related]
19. CIP2A mediates prostate cancer progression via the c-MYC signaling pathway.
Guo Z; Liu D; Su Z
Tumour Biol; 2015 May; 36(5):3583-9. PubMed ID: 25560487
[TBL] [Abstract][Full Text] [Related]
20. CIP2A facilitates apoptotic resistance of fibroblast-like synoviocytes in rheumatoid arthritis independent of c-Myc expression.
Lee J; Jeong H; Park EJ; Hwang JW; Huang B; Bae EK; Ahn JK; Cha HS; Koh EM
Rheumatol Int; 2013 Sep; 33(9):2241-8. PubMed ID: 23455633
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
